| For: | Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World J Clin Cases 2022; 10(8): 2569-2576 [PMID: 35434082 DOI: 10.12998/wjcc.v10.i8.2569] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i8/2569.htm |
| Number | Citing Articles |
| 1 |
Afsaneh Shirani, Olaf Stuve. Vedolizumab and the gut–CNS axis in multiple sclerosis: considering T cell licensing pathways. Therapeutic Advances in Neurological Disorders 2026; 19 doi: 10.1177/17562864261423751
|
| 2 |
Tiffany Kim, Allen Brinker, David Croteau, Paul R Lee, Laura E Baldassari, Jessica Stevens, Alice Hughes, Juli Tomaino, Arushi deFonseka, Tara Altepeter, Cindy M Kortepeter. Immune-mediated colitis associated with ocrelizumab: A new safety risk. Multiple Sclerosis Journal 2023; 29(10) doi: 10.1177/13524585231195854
|
| 3 |
M. Dominguez-Gallego, V. Meca-Lallana, A.B. Caminero. Inflammatory bowel disease and multiple sclerosis. Neurology Perspectives 2025; 5(3) doi: 10.1016/j.neurop.2025.100199
|
| 4 |
Beatriz Gros, Gaëlle Varkas, Reinhart Speeckaert, Triana Lobaton. Combining advanced therapies in patients with inflammatory bowel disease and extraintestinal manifestations or associated immune-mediated diseases: who, what, when and at what cost?. Frontline Gastroenterology 2025; doi: 10.1136/flgastro-2024-102967
|
| 5 |
Shellie Radford, Daniel Arruda Navarro Albuquerque, Zara Najeeb, Debangsh Agarwal, Anoop John, Morris Gordon, Vassiliki Sinopoulou, Gordon Moran. Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis. BMJ Open Gastroenterology 2026; 13(1) doi: 10.1136/bmjgast-2026-002307
|
| 6 |
Javier P Gisbert, María Chaparro. Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review. Journal of Crohn's and Colitis 2025; 19(9) doi: 10.1093/ecco-jcc/jjaf161
|
| 7 |
Vittorio Viti, Chiara Zanetta, Ruggero Capra, Andrea Municchi, Maria A. Rocca, Massimo Filippi. Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue. Journal of Neurology 2024; 271(9) doi: 10.1007/s00415-024-12553-4
|
| 8 |
Anne-Laure Gérard, Matheus Vieira, Ariel Cohen, Olivier Hassanaly, Jérôme Lambert, David Saadoun. Combotherapies in immune-mediated inflammatory diseases: A study using the Clinical Data Warehouse from Paris Hospitals’ Public Assistance. Seminars in Arthritis and Rheumatism 2025; 71 doi: 10.1016/j.semarthrit.2025.152660
|
| 9 |
Cristina Bezzio, Cristina Della Corte, Marta Vernero, Imma Di Luna, Gianpiero Manes, Simone Saibeni. Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221115312
|
| 10 |
Vittorio Viti, Chiara Zanetta, Maria A Rocca, Massimo Filippi. Immune-mediated colitis: A class effect with anti-CD2O agents used to treat MS?. Multiple Sclerosis Journal 2025; 31(2) doi: 10.1177/13524585241303480
|
| 11 |
A. Quesada-Simó, A. Garrido-Marín, P. Nos, S. Gil-Perotín. Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship with de novo intestinal bowel disease in multiple sclerosis: a review. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1186016
|
| 12 |
Ileana Maria Vodă, Vlad Eugen Tiu, Luiza Răuță, Paul Ciucur, Andreea Ioana Mușuroi, Alina Flavia Tomescu, Nicoleta Laura Humă, Florin Dobrițoiu, Elena Terecoasă, Lucian Negreanu, Cristina Tiu. Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients. Frontiers in Neurology 2025; 16 doi: 10.3389/fneur.2025.1530438
|
| 13 |
Haddad S, Perrotta G, Pezzullo M, Franchimont D, Elands S. Colitis and pancreatitis following ocrelizumab therapy for multiple sclerosis: a report of two cases. Neuroimmunology Reports 2026; 9 doi: 10.1016/j.nerep.2026.100279
|
| 14 |
Bindu Challa, Ashwini Kumar Esnakula. Histologic manifestations of ocrelizumab‐associated intestinal and hepatic injury in patients with multiple sclerosis. Histopathology 2024; 84(5) doi: 10.1111/his.15120
|
| 15 |
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen. Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review. British Journal of Clinical Pharmacology 2026; doi: 10.1002/bcp.70490
|
| 16 |
Sailish Honap, Marc Debouverie, Massimo Filippi, Daniel Selchen, Vipul Jairath, Silvio Danese, Laurent Peyrin-Biroulet. Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk. Journal of Crohn's and Colitis 2026; 20(1) doi: 10.1093/ecco-jcc/jjaf215
|
| 17 |
Sarah Tolaymat, Kanika Sharma, Yusuf Kagzi, Shitiz Sriwastava. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review. Multiple Sclerosis and Related Disorders 2023; 75 doi: 10.1016/j.msard.2023.104763
|